Both, in terms of bottomline and stock price performance, pharma stocks had been under pressure for a long time. Partly this under performance was due to over valuation at which these companies were trading since 2015. Also stocks came in the overowned category for both the institutional and retail investors portfolio. Last but not the least, close to 2014, USFDA inspections became both more in numbers and stricter, many companies which assumed that they can take care of anything, got a rude shock. After all the head and tailwinds, many companies which had changed their focus, fruits are visible in terms of them moving into new markets and better financials.
Related Keywords
India , China , , Market Research , Google , Unlimited Access , Economic Times , Saver Sale , Membershipclaim Offer , Prime Story , Debit Cards , Includes Docubay , Economic Times Stories , Industry Trends , Virtual Events , Torrent Pharmaceuticals , Pharma Stocks To Buy , Pharma Stocks , Pharma Stock Picks , Pharma Stock Ideas , Indoco Remedies , Indian Pharma Stocks , Granules India , Glenmark Life Sciences , Aarti Drugs ,
comparemela.com © 2020. All Rights Reserved.